|Bid||0.1389 x 21500|
|Ask||0.4445 x 1000|
|Day's Range||0.4265 - 0.4473|
|52 Week Range||0.3900 - 2.3600|
|Beta (3Y Monthly)||1.81|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 6, 2018 - Aug 10, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||26.00|
Germantown-based Neuralstem Inc. has been put on notice that its stock could be delisted from the Nasdaq if the company can’t raise its share price above $1 continually within the next six months. The stem cell therapy company said it intends to continue actively monitoring its common stock price and will consider options to boost its value. To return to compliance, Neuralstem stock must close at or above $1 per share for at least 10 consecutive days, though the company could file for an extension or appeal.
Neuralstem Inc (NASDAQ:CUR), which has zero-debt on its balance sheet, can maximize capital returns by increasing debt due to its lower cost of capital. However, the trade-off is CUR will Read More...
NEW YORK, Nov. 19, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- NSI-189 Received Orphan Designation for Treatment of Angelman Syndrome - - Initiated Phase 2 Clinical Trial of NSI-566 for Treatment of Chronic Stroke - -.
Neuralstem, Inc. (CUR), a biopharmaceutical company focused on developing novel treatments for nervous system diseases, today announced that it has entered into definitive agreements with institutional investors for the purchase of 3,000,000 shares of its common stock, at a purchase price per share of $0.70, in a registered direct offering. Additionally, Neuralstem has also agreed to issue to the investors unregistered warrants to purchase up to 3,000,000 shares of its common stock. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.
Neuralstem, Inc. (CUR), a biopharmaceutical company focused on developing novel treatments for nervous system diseases, announced the publication of a manuscript in Scientific Reports showing that transplantation of NSI-532.IGF1, a proprietary human neural stem cell line developed by Neuralstem (US patent no 9,750,769), mitigates disease pathology and improves cognition in a mouse model of Alzheimer’s disease (AD). The study was performed at the University of Michigan by a team led by Dr. Eva Feldman, Director of the Program for Neurology Research and Discovery, and Research Director of the University of Michigan ALS Center of Excellence.
If you own shares in Neuralstem Inc (NASDAQ:CUR) then it’s worth thinking about how it contributes to the volatility of your portfolio, overall. In finance, Beta is a measure ofRead More...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on July 31) Allakos Inc (NASDAQ: ALLK ) (listed July 19 following its IPO) ...
Stock Monitor: Neuralstem Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 18, 2018 / Active-Investors.com has just released a free research report on Idera Pharma, Inc. (NASDAQ: IDRA ) ("Idera"). ...
NEW YORK, NY / ACCESSWIRE / April 11, 2018 / U.S. equities regained their footing on Tuesday, as trade tensions between the U.S. and China calmed after comments from the Chinese President Xi Jinping. The ...